Azenta upgraded to Buy from Hold at Jefferies

Jefferies upgraded Azenta (AZTA) to Buy from Hold with a price target of $38, up from $30. The firm sees an attractive setup for the shares into 2026. The company has “healthy” biopharma exposure and “plenty of growth drivers” from innovation, pricing, attach rates and potential acquisitions, the analyst tells investors in a research note. Jefferies believes the shares can re-rate higher as investors gain confidence in Azenta’s mid-term opportunity.